London, United Kingdom (PressExposure) April 28, 2011 -- GlobalData's analysis suggests that the global dermatophytic onychomycosis therapeutics market was valued at $2.1 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7% over the next seven years, to reach $3.4 billion by 2017. The steady growth is primarily attributed to the usage of generics and the entry of new nmolecule (AN-2690) as a topical therapy with a novel mechanism of action.
The current market for dermatophytic onychomycosis is weak. Although the current market is served by generic drugs which have high efficacy and few adverse effects, there is still scope for new entrants with disease-modifying mechanisms which would be able to serve the unmet need of the market in the near future. The development pipeline is also weak, with few first-in-class molecules. There are products in the pipeline with the same mode of action as current therapies but with the involvement of new technologies, like Meltrex for Hyphanox (itraconazole) and Transfersome for TDT-067 (terbinafine hydrochloride) would further improve the efficacy and safety of the molecule. These molecules with new technologies would fulfill the unmet need of the market.
For Sample Pages, please click or add the below link to your browser:
The current market is found to be weak because terbinafine is the only molecule with high efficacy and few adverse events, in comparison to the other marketed products. In the pipeline, most of the first-inclass molecules to be found are in the early stages of development and the molecules in Phase III trials and regulatory filings are either me-too drugs or generics. The molecules which are expected to be launched in the coming years may not have a significant impact on the market, as they are either generics or in a topical form. The drugs in the topical form are generally unable to cure dermatophytic onychomycosis as they cannot penetrate deep the nail to treat the infection. So, the weak current competition and weak pipeline means the dermatophytic onychomycosis therapeutic market is likely to be static for the foreseeable future, which will lead to a market share war for the future players.
The research indicates that the dermatophytic onychomycosis therapeutics pipeline is weak. The first-inclass molecules seem to have a distinct advantage over the current available drugs. The unmet need of the dermatophytic onychomycosis therapeutics market is low. The treatment relies on generic drugs and the market needs novel therapies offering better results in terms of safety and efficacy.
GlobalData, the industry analysis specialist, has released its new report, "Dermatophytic Onychomycosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global dermatophytic onychomycosis market. The report identifies the key trends shaping and driving the global dermatophytic onychomycosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dermatophytic onychomycosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782